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Received March 18, 2010; accepted August 11, 2010AbstractExtramammary Paget’s disease of the scrotum with sweat gland adenocarcinoma is a rare malignant tumor. This study aims to summarize the
clinicopathologic characteristics related to the prognosis of scrotal Paget’s disease with underlying sweat gland adenocarcinoma. Clinical datum
of four patients with scrotal Paget’s disease with sweat gland carcinoma, treated in Beijing Chao-Yang Hospital from 2002 to 2009 was analyzed,
and a literature review was conducted. The typical manifestation of scrotal Paget’s disease with sweat gland carcinoma was eczematoid-like skin
lesions. All patients underwent primary lesion resection plus inguinal lymphadenectomy. Three patients had inguinal lymph metastasis. One of
them developed distant metastases in bone and bone marrow and died of metastatic carcinoma. The dead patient had higher serum carcinoma
embryonic antigen (CEA) level, Her-2 overexpression and shorter disease course than the other patients. The other patients were observed for at
least 3 years, and lived without tumor. Scrotal Paget’s disease with sweat gland adenocarcinoma may be prone to inguinal lymph node and bone
metastasis. Serum CEA level, Her-2 overexpression, dermis and lymphovascular invasion may be associated with the prognosis of scrotal Paget’s
disease with sweat gland adenocarcinoma. The primary lesion resection plus inguinal lymphadenectomy is the major treatment for scrotal
Paget’s disease with sweat gland adenocarcinoma. The effect of combination chemotherapy in the treatment of metastatic extramammary Paget’s
disease remains to be proven by prolonged follow-up and wide experience.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Most often, Paget’s disease occurs around the nipple as
a consequence of the intraepidermal spread of an underlying
mammary carcinoma. Paget’s disease also occurs at extra-
mammary sites, mostly in the genitoanal skin in women,
whereas genitoanal extramammary Paget’s disease (EMPD) in
men is rare, and only small series of case reports have been
reported (Table 1). The tumor cells in Paget’s disease have* Corresponding author. Dr. Dong Yan, Department of Oncology, Beijing
Chao-Yang Hospital Affiliated with Capital Medical University, Beijing
100020, China.
E-mail address: yd15yt88@163.com (D. Yan).
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doi:10.1016/j.jcma.2011.01.040abundant pale cytoplasm and large pleomorphic nuclei and
contain mucopolysaccharides which are positive with PAS and
alcian blue methods in about 60% of cases. The origin of these
cells is unclear; most authors assume a relationship to apocrine
glands because they occur in apocrine gland-bearing skin1 and
most but not all Paget cells stain positively for GCDFP-15,
a marker of apocrine cells.2
About 25% of all cases have an underlying cutaneous
adnexal carcinoma, mostly of apocrine type. A further 10% of
patients have an internal carcinoma. EMPD of the scrotum
with sweat gland adenocarcinoma is extremely rare.3 We
analyze the clinicopathologic features of four scrotal Paget’s
disease patients with sweat gland adenocarcinoma.hinese Medical Association. All rights reserved.
Table 1
Summary of the literature review
Author Publication date (year) Article type Topic No of cases Ref.
Zhang et al. 2006 Retrospective study Pathology 23 10
Pascual et al. 2008 Case report Scrotal EMPD 1 7
Aldewereld & Blanken 2009 Case report Scrotal EMPD 1 1
Tu et al. 2009 Case reports and review Scrotal EMPD with sweat gland adenocarcinoma 6 3
Plaza et al. 2009 Retrospective study Skin neoplasms 47 8
Zhu et al. 2009 Retrospective study Penoscrotal EMPD 43 9
Takahagi et al. 2009 Case report Metastatic EMPD/targeted treatment 1 12
Zhang et al. 2010 Case reports and review Scrotal EMPD 25 4
EMPD¼ extramammary Paget’s disease.
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Four male patients were initially treated for irritant and
allergic contact dermatitis with topical creams in Beijing
Chao-Yang Hospital. The median age was 61.0 years (range,
59.0e68.0 years). All the patients presented an oval-shaped,
eczematoid, non-scaly, tender and erythematous lesion with
surrounding clear uplift belts on the scrotum with a diameter
of approx 3e5 cm. Results of physical examination were
normal except for skin findings. There was no evidence of
malignancy on abdominal and chest computed tomography
examination. Serum CEA level was normal in three cases.
Accompanying progression of the disease, three patients had
palpable enlarged inguinal lymph nodes. All patients under-
went a wide resection of the primary lesion plus inguinal
lymphadenectomy. The three patients diagnosed with inguinal
lymph node metastasis were treated with postoperative
radiotherapy and administered under 5-fluorouracil-based
adjuvant chemotherapy (Table 2). Histological examination of
the resected specimen in the four cases led to the diagnosis
of scrotal Paget’s disease with sweat gland adenocarcinoma
(Fig. 1). Additionally, immunohistologic staining revealed
positive reactions to CEA, AE1/AE3, CAM5.2, Her-2 and
strongly positive reaction to the apocrine marker GCDFP-15.Table 2
Details of the four patients of scrotal Paget’s disease with sweat gland adenocarci
Clinical data Case 1 C
Gender Male M
Age (yr) 59 6
Lesion diameter (cm) 5.00 3
Serum CEA level (normal 3.40 ng/mL) 263.70 1
Lymph node status (metastasis/dissection) 2/3 1
Primary treatment Surgery S
c
a
Relapse/metastasis Bone and bone
marrow metastasis
N
Immunohistochemistry
CEA þ þ
AE1/AE3 þ N
CAM5.2 þ þ
GCDFP15 þ þ
Her-2 þþþ þSections of inguinal lymph nodes showed metastatic adeno-
carcinoma in three cases. Among the three patients, one also
had involvement in the dermis of the scrotum and groin. The
patient was diagnosed with bone and bone marrow metastases
by bone scan, bone marrow biopsy (Fig. 2) and morphocy-
tology (Fig. 3) after operation, accompanied with elevated
serum CEA, T-PSA, CA125, CA199 and CA72.4 level.
Immunohistologic staining identified metastatic adenocarci-
noma with CK8/18 (þ), CEA (þ), EMA (þ), 34BE12 (þ),
CK5/6 (), P63 () and PAS (þ). The patient received one-
cycle chemotherapy of NP regimen (vinorelbine 40 mg on
Day 1þ cisplatin 40 mg on Days 2e4). The most serious
toxicity reaction was bone marrow suppression of grade Ⅲ.
The patient died with epistaxis and subcutaneous bleeding
eventually. The overall survival time was 6 months. Other
patients were observed for at least 3 years, and lived without
tumor.
3. Discussion
Most of patients with scrotal Paget’s disease are middle-
aged or elderly people (>50 years old). The initial manifes-
tation of the disease includes redness, roughness and itchiness
of the skin lesion. Metastasis is reportedly less common.4noma
ase 2 Case 3 Case 4
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0 62 68
.50 3.50 3.00
.92 2.41 2.04
/3 0/2 1/2
urgery plus adjuvant
hemotherapy
nd radiotherapy
Surgery plus
chemotherapy
Surgery plus adjuvant
chemotherapy
and radiotherapy
o No No
þ þ
o þ No
No þ
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Fig. 3. Morphocytology of bone marrow (tumor cells were seen in bone
marrow 1000).
Fig. 1. Histopathology of scrotal lesions (tumor cells with bright cytoplasm,
heteromorphic nuclear, thick nuclear membrane and marked nuclei were
identified in epidermis 400).
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apocrine and eccrine glands, sweat ducts, or secretory portion.
The lesion grows slowly and is prone to recurrence after
resection. The lymph node is commonly affected. The carci-
noma expands regionally in early stage, and hematogenous
spread or bone metastasis may occur subsequently.5 The
relationship between them has drawn much attention.
Whether the EMPD Paget cells are from adenocarcinoma
cells or epidermal keratinocytes is still under debate. Immu-
nohistochemistry revealed that Paget cells share similar
structure with those of the apocrine gland. Accordingly, some
scholars proposed that sweat gland adenocarcinoma and
EMPD might originate from similar tissue, and the former was
the development and metastatic form of EMPD, whereas
EMPD was an early metastatic form of sweat gland adeno-
carcinoma. Other scholars considered that EMPD was
a special type of skin in situ carcinoma and the cancer cells
were derived from pluripotent dermocytes, whereby spreading
to the underlying breast gland, hair follicle, sweat gland andFig. 2. Histopathology of bone marrow (adenoid cancer cells were seen in the
bone marrow biopsy specimen 400).apocrine ducts.6 Recent studies of perianal and vulvar EMPD
described distinct immunohistochemical subtypes, termed as
cutaneous and endodermal. Cutaneous EMPD was character-
istically positive for cytokeratin (CK)7, negative for CK20,
and positive for gross cystic disease fluid protein (GCDFP)
15þ, whereas endodermal EMPD showed a CK7þ, CK20þ,
GCDFP-15 phenotype.7 In the current study, the immunohis-
tochemistry of four patients of scrotal Paget’s disease with
sweat gland adenocarcinoma showed CEAþ, GCDFP-15þ,
Her-2 wþþþ. We suggest sweat gland adenocarcinoma
was the development and metastasis of scrotal Paget’s disease.
Her-2 overexpression implied a more aggressive behavior
in breast cancer. Plaza8 found the overall Her-2/neu expres-
sion was 31.9% in EMPD with and without underlying
malignancy by immunohistochemistry. Zhu et al.9 indicated
serum CEA level can be a useful biomarker for monitoring
disease course. Dermal or deeper invasion, lymphovascular
embolization and negative expression of E-cadherin were
important pathological predictors of metastasis. As has been
found previously in metastatic EMPD, the dead patient had
dermis and lymphovascular invasion, higher serum CEA level,
Her-2 overexpression and shorter disease courses than the
other patients.
The management of scrotal Paget’s disease with sweat
gland carcinoma is primarily surgical operation. Unfortu-
nately, there is a high rate of recurrence, up to 50% depending
on the method of surgery, because the disease often extends
beyond the clinically visible margins.10,11 However, the role of
chemotherapy in metastatic EMPD with sweat gland carci-
noma is uncertain. Zhu et al.9 administered 5-fluorouracil- or
docetaxel-based chemotherapy to metastatic EMPD patients,
CR 20%, RR 50%, PD50%, and 2-year overall survival rate
was 48%. Takahagi et al.12 treated a 75-year-old patient of
HER2-positive metastatic scrotal Paget’s disease with pacli-
taxel and trastuzumab. Histopathological examination showed
that most of HER2-positive tumor cells diminished during the
regimen. In our study, all the present cohort patients had
received surgical operation. The resection extension included
182 D. Yan et al. / Journal of the Chinese Medical Association 74 (2011) 179e182skin 2e3 cm off the primary lesion and the subcutaneous
adipose tissues. Three patients without recurrence had received
postoperative radiotherapy and chemotherapy, the dead patient
underwent one course of palliative chemotherapy of NP
regimen. The overall survival time was 6 months, and the
major toxicities were grade Ⅲ neutropenia and thrombocyto-
penia, respectively.
In conclusion, serum CEA level, Her-2 overexpression,
dermis and lymphovascular invasion may be associated with
the prognosis of scrotal Paget’s disease with sweat gland
adenocarcinoma. Combination chemotherapy may be consid-
ered in cases of inadequately excised microscopic lesion and
its efficacy remains to be proven by prolonged follow-up and
wide experience in metastatic scrotal Paget’s disease with
sweat gland adenocarcinoma.
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